Summary
- Selecta Biosciences enabled a restructuring of its pipeline to save cash and advance its chronic gout drug forward known as SEL-212.
- By reducing its workforce by 36% as of January 3, 2019, the company will reduce the yearly cash burn by as much as 19% going forward.
- SEL-212 had already reported a positive interim updated from its phase 2 study, proving that 21 out of 32 maintained serum uric acid (sUA) levels of <6mg/dL.
- A head-to-head study pitting SEL-212 against Krystexxa is expected to begin possibly by Q1 of 2019.
- SEL-212 has a component known as SVP-Rapamycin, which is responsible for countering the anti-drug antibodies that occur when patients are treated with many other chronic gout therapies.
- Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our model portfolio. Start your free trial today ยป
Selecta Biosciences (SELB) had done a restructuring a few weeks ago, and it is set to start a head-to-head study in the current quarter. The company will be starting a study to compete in the chronic gout space. I believe that with the stock trading so low at $2.04 per share, there is plenty of upside potential based on the market opportunity. For that reason, I believe Selecta Biosciences is a good speculative buy.

